If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
160
results.
Updated on
23/10/2025 [06:57:00]
Absstract of: EP4635416A2
The present invention relates to a sensor applicator assembly for a continuous glucose monitoring system and provides a sensor applicator assembly for a continuous glucose monitoring system, which is manufactured with a sensor module assembled inside an applicator, thereby minimizing additional work by a user for attaching the sensor module to the body and allowing the sensor module to be attached to the body simply by operating the applicator, and thus can be used more conveniently. A battery is built in the sensor module and a separate transmitter is connected to the sensor module so as to receive power supply from the sensor module and be continuously used semi-permanently, thereby making the assembly economical. The sensor module and the applicator are used as disposables, thereby allowing accurate and safe use and convenient maintenance.
Absstract of: EP4635406A2
The present invention relates to a continuous blood glucose measurement device which is produced with an assembled body attachment unit inside an applicator so as to minimize a user's additional work of attaching the body attachment unit to the body, thereby enabling the body attachment unit to be attached to the body by simply activating the applicator, and, particularly, the present invention provides a continuous blood glucose measurement device which: is provided with a wireless communication chip in a body attachment unit so as to enable communication with an external terminal, thereby enabling simple and convenient use, without additional work of connecting a separate transmitter, and easier maintenance; and is activated by the user after the body attachment unit is attached to the body so as to enable the operation start time to be adjusted to an appropriate time according to user's needs, and to enable the operation to start in a stabilized state so that blood glucose can be measured more accurately.
Absstract of: EP4635409A2
The present disclosure relates to a method for stabilizing a continuous glucose monitoring system. The method for stabilizing a continuous glucose monitoring system according to an embodiment of the present invention may comprise: a step of measuring biometric information by a sensor transmitter disposed in a part of a user's body so as to measure the user's biometric information; a step of transmitting, by the sensor transmitter, data on the measured biometric information (biometric information data) to a communication terminal; a stabilization step of stabilizing, by the communication terminal, the biometric information data received from the sensor transmitter; and a step of displaying, by the communication terminal, the biometric information data after the stabilizing step is completed, so as to allow the user to identify the biometric information data received from the sensor transmitter, wherein in the stabilization step, the communication terminal variably controls the time during which the biometric information data received from the sensor transmitter is stabilized. The present disclosure has an advantage in that the time during which data measured by a sensor transmitter is stabilized can be variably controlled according to sensor transmitters, and thus accurate biometric information data can be provided to a user.
Absstract of: US2025319254A1
Techniques disclosed herein relate to managing operations of a dual-mode insulin delivery device that can operate in a manual insulin delivery mode and an automated closed-loop insulin delivery mode. In one example, a processor-implemented method includes obtaining insulin delivery data of an insulin delivery device collected while the insulin delivery device operates in a closed-loop mode, determining an updated value of a parameter of the insulin delivery device in a manual mode based on the insulin delivery data, and causing the insulin delivery device to deliver insulin in the manual mode based on the updated value of the parameter of the insulin delivery device, where the parameter of the insulin delivery device has separate values in the manual mode and the closed-loop mode.
Absstract of: US2025319256A1
In an aspect, the present disclosure provides an insulin delivery device configured to be positioned on a body of a subject via a single puncture site in said body of said subject, wherein said insulin delivery device is configured to deliver an insulin or insulin analog formulation to said subject via said single puncture site, wherein said insulin delivery device comprises a sensor configured to measure a glucose concentration in said body of said subject via said single puncture site, and wherein said delivering and said measuring are performed at substantially the same time for a time period of at least 1 hour subsequent to said positioning, while maintaining a sensitivity of said sensor of at least 50% of an initial sensitivity of said sensor.
Absstract of: US2025319257A1
The embodiments described herein may relate to methods and systems for adjusting insulin delivery. Some methods and systems may be configured to adjust insulin delivery to personalize automated insulin delivery for a person with diabetes. Some methods and systems may be configured to adjust insulin delivery to a person with diabetes according to one or more conditions of an insulin delivery device. Some methods and systems may be configured to enable a lock-out mode where adjustment to insulin delivery to personalize automated insulin delivery is restricted.
Absstract of: WO2025216237A1
This blood glucose level measurement device comprises: a light output unit that outputs light; a light detection unit that detects the light output by the light output unit and transmitted through a living body; a temporal phase difference calculation unit that calculates, on the basis of the detection result from the light detection unit, a temporal phase difference between an oxygenated hemoglobin waveform pertaining to the oxygenated hemoglobin concentration in blood of the living body and a deoxygenated hemoglobin waveform pertaining to the deoxygenated hemoglobin concentration in the blood of the living body; a blood glucose level calculation unit that calculates the blood glucose level of the living body on the basis of the calculated temporal phase difference; and a confidence level estimation unit that estimates the confidence level of the calculated temporal phase difference. The confidence level estimation unit estimates that the confidence level of the temporal phase difference is lower when the SN ratio of the detection result from the light detection unit is lower.
Absstract of: WO2025217456A1
Methods, systems, and devices for evaluating a user's metabolic balance are described. A system may include a wearable device and a glucose monitoring device. The system may acquire physiological data from the wearable device, and blood glucose data from the glucose monitoring device. The system may be configured to determine physiological characteristics of the user based on the physiological data, such characteristics associated with a sleep quality of the user, a stress level of the user, an activity level of the user, a recovery of the user, or any combination thereof. Similarly, the system may identify metabolic characteristics of the user, such as changes in the user's blood glucose data. By overlaying and comparing the physiological data and the blood glucose data, the system may be able to evaluate how the user's physiological characteristics affect or impact the user's metabolic characteristics, or vice versa.
Absstract of: WO2025216236A1
This blood sugar level measurement apparatus comprises an estimation unit that estimates blood sugar levels in a living body by using a trained machine learning model. The machine learning model is a model for outputting output data relating to a blood sugar level by inputting, as an input parameter, at least a temporal phase difference between oxygenated hemoglobin and deoxygenated hemoglobin in blood of a living body.
Absstract of: WO2025216649A1
The invention relates to medicine and technology, and more particularly to non-invasively detecting a change in a person's blood glucose concentration, and can be used in the creation of devices for this purpose, as well as in the creation of socially-oriented systems for the early diagnosis of diabetes and associated diseases, in the form of a pen. The aim of the invention is to improve the operational efficiency of a device for non-invasively checking a person's blood glucose concentration by reducing the set-up and configuration time required. This aim is achieved in that a device for non-invasively checking a person's blood glucose concentration is based on a pen and has a sensor disposed on one end of a housing, opposite an end containing a device for applying ink to a surface. The technical results of the invention include: obviating the need for the device to be worn on an arm; simplifying the device by the absence of a strap and by incorporation of the device into a pen; and making it possible to visually check the correct positioning of the sensor of the device on a pulse point.
Absstract of: WO2025216456A1
The present invention generally relates to implantable continuous blood glucose measurement technology. In particular, the present invention relates to an implantable continuous blood glucose measurement device for continuously measuring blood glucose in the body of a user, in which an oscillator for generating a variable frequency output signal corresponding to a voltage or current applied to both ends thereof is connected to a glucose fuel cell for generating electrical energy by glucose in the body, comprises an LED element, which is turned on or off by the output signal of the oscillator, or an antenna for wirelessly transmitting the output signal of the oscillator. The present invention has the advantage that blood glucose can be continuously measured in a state in which a blood glucose sensor is implanted in the body, without having to replace same.
Absstract of: WO2025217563A1
A device for continuously monitoring glucose levels in a patient includes a lead assembly in electrical communication with an electronics assembly. The electronics assembly is configured to be positioned in the subcutaneous tissue and the lead assembly is configured to be positioned in a vessel of the patient, such as in a vein or in an epidural space. The lead assembly has a lumen, and includes at least one electrode in electrical communication with the electronics assembly.
Absstract of: WO2025217339A1
Certain aspects of the present disclosure provide a monitoring system comprising one or more memories comprising executable instructions and one or more processors in data communication with the one or more memories and configured to execute the executable instructions to calculate a gastric emptying rate of a patient based on glucose measurements and lactate measurements and determine whether the gastric emptying rate of the patient is decreasing. The one or more processors are further configured to determine, if the gastric emptying rate of the patient is decreasing, whether the gastric emptying rate of the patient meets a first threshold, or whether a reduction in the gastric emptying rate over a defined period of time meets a second threshold, provide therapy management action to the patient based on the gastric emptying rate of the patient to optimize the gastric emptying rate of the patient, and recalculate, following the therapy management action, the gastric emptying rate of the patient based on the glucose measurements and the lactate measurements.
Absstract of: US2025318759A1
Systems and methods are described herein for utilizing a photoacoustic sensor for estimating analyte concentration levels. Also described here are calibration and training methods for calibrating and/or training an analyte sensor to more accurately estimate an analyte concentration level on the basis of a received acoustic signal.
Absstract of: US2025318758A1
A device for continuously monitoring glucose levels in a patient includes a lead assembly in electrical communication with an electronics assembly. The electronics assembly is configured to be positioned in the subcutaneous tissue and the lead assembly is configured to be positioned in a vessel of the patient, such as in a vein or in an epidural space. The lead assembly has a lumen, and includes at least one electrode in electrical communication with the electronics assembly.
Absstract of: US2025318756A1
A device for continuously monitoring glucose levels in a patient includes a lead assembly in electrical communication with an electronics assembly. The electronics assembly is configured to be positioned in the subcutaneous tissue and the lead assembly is configured to be positioned in a vessel of the patient, such as in a vein or in an epidural space. The lead assembly has a lumen, and includes at least one electrode in electrical communication with the electronics assembly.
Absstract of: US2025318729A1
Disclosed embodiments include methods and systems including a receiver unit of a glucose monitoring system. The receiver unit is configured to receive a key associated with a transmitter unit that enables the receiver unit to identify the transmitter unit, initiate communication with the transmitter unit, access a communication key uniquely associated with the transmitter unit, and receive communication packets from the remote transmitter unit on a periodic basis including data indicative of a glucose level of a bodily fluid. The receiver unit is further configured to process the data determine the glucose level for display, output a numerical representation of the determined glucose level in a GUI, and transmit data indicative of the glucose level to a second receiver unit.
Absstract of: US2025318755A1
Methods, systems, and devices for evaluating a user's metabolic balance are described. A system may include a wearable device and a glucose monitoring device. The system may acquire physiological data from the wearable device, and blood glucose data from the glucose monitoring device. The system may be configured to determine physiological characteristics of the user based on the physiological data, such characteristics associated with a sleep quality of the user, a stress level of the user, an activity level of the user, a recovery of the user, or any combination thereof. Similarly, the system may identify metabolic characteristics of the user, such as changes in the user's blood glucose data. By overlaying and comparing the physiological data and the blood glucose data, the system may be able to evaluate how the user's physiological characteristics affect or impact the user's metabolic characteristics, or vice versa.
Absstract of: AU2025200899A1
An embodiment may provide a method of providing an event notification in a glucose monitoring system, the method including determining whether an event occurs; in response to the occurrence of the event, determining whether an event occurrence time falls within a signal loss section; and outputting a notification corresponding to the event depending on whether the event occurrence time falls within the signal loss section. An embodiment may provide a method of providing an event notification in a glucose monitoring system, the method including determining whether an event occurs; in response to the occurrence of the event, determining whether an event occurrence time falls within a signal loss section; and outputting a notification corresponding to the event depending on whether the event occurrence time falls within the signal loss section. eb n e m b o d i m e n t m a y p r o v i d e a m e t h o d o f p r o v i d i n g a n e v e n t n o t i f i c a t i o n i n a e b g l u c o s e m o n i t o r i n g s y s t e m , t h e m e t h o d i n c l u d i n g d e t e r m i n i n g w h e t h e r a n e v e n t o c c u r s ; i n r e s p o n s e t o t h e o c c u r r e n c e o f t h e e v e n t , d e t e r m i n i n g w h e t h e r a n e v e n t o c c u r r e n c e t i m e f a l l s w i t h i n a s i g n a l l o s s s e c t i o n ; a n d o u t p u t t i n g a n o t i f i c a t i o n c o r r e s p o n d i n g t o t h e e v e n t d e p e n d i n g o n w h e t h e r t h e e v e n t o c c u r
Absstract of: AU2025237952A1
PORTABLE DEVICE AND METHOD FOR NON-INVASIVE BLOOD GLUCOSE LEVEL ESTIMATION The invention relates to a device (1) comprising a measuring unit (2) with a measuring module (4) for measuring the glucose level, a first computer module (5) for processing data from a first part of the process for measuring the glucose level, a first communications module (6), a first data storage module (7) and a pushbutton (8). The device also comprises a personal monitoring unit (3) with second and third 10 communication modules (17, 20), a second computer module (18) for processing data from a second part of the process for measuring the glucose level, an interface module (19) and a second data storage module (22). Also described is a method for non- invasive blood glucose level estimation. PORTABLE DEVICE AND METHOD FOR NON-INVASIVE BLOOD GLUCOSE LEVEL ESTIMATION The invention relates to a device (1) comprising a measuring unit (2) with a measuring module (4) for measuring the glucose level, a first computer module (5) for processing data from a first part of the process for measuring the glucose level, a first communications module (6), a first data storage module (7) and a pushbutton (8). The 10 device also comprises a personal monitoring unit (3) with second and third communication modules (17, 20), a second computer module (18) for processing data from a second part of the process for measuring the glucose level, an interface module (19) and a second data storage module (22). Also described
Absstract of: US2025319255A1
A method may comprise (a) inserting an insulin delivery device subcutaneously into a body of a subject, which comprises an amperometric glucose sensor comprising an electrode layer comprising an indicating electrode and underlying a redox-catalytic layer comprising a redox mediator; (b) using said insulin delivery device to deliver an insulin formulation (e.g., comprising a phenol or cresol excipient) subcutaneously to said subject; and (c) using said amperometric glucose sensor to measure a subcutaneous glucose concentration, which comprises using said redox-catalytic layer to allow electron transfer from subcutaneous glucose to said indicating electrode sufficient to cause a response of said amperometric glucose sensor at an applied bias potential of no more than +250 millivolts, wherein (b) and (c) are performed at the same time for at least one hour, while maintaining a sensor sensitivity of at least 50% of an initial sensor sensitivity for up to one hour.
Absstract of: NL1044854B1
The invention is related to a device and method for the intravenously administered administration of hormones with the aim to regulate and control, for example, a desired euglycemic homeostatic condition for individuals suffering from diabetes type 1. The hormone dose effect on the desired condition is periodically evaluated dependent on the half-life value of the administered hormone by means of measurement of the desired concentration in plasma. In this invention an intravenous method of administration of the hormone in the form of a micro bolus is used because the commonly applied method of subcutaneous administration results in an undefined and unreliable transfer of the hormone to the blood compartment which results in problems to realize an optimal unattended closed loop control system. This invention relates to a device and method using the intravenous administration of the hormones insuli n and glucagon according to their half-life properties in order to attain automatically the desired state of glucose homeostasis using continuous glucose sensors providing the electronic device with the necessary control data. The results of the proceseed data are sent, dependent on the glucose concentration, to control a here not defi lied separate insulin and glucagon pump, which administers the hormone in the form of a micao bolus. This micro bolus is always too small to cause any risk for the user. The device and method are applieable for every individual in order to control and
Absstract of: US2025318757A1
A device for continuously monitoring glucose levels in a patient includes a lead assembly in electrical communication with an electronics assembly. The electronics assembly is configured to be positioned in the subcutaneous tissue and the lead assembly is configured to be positioned in a vessel of the patient, such as in a vein or in an epidural space. The lead assembly has a lumen, and includes at least one electrode in electrical communication with the electronics assembly.
Absstract of: US2025318763A1
Systems and methods of use for continuous analyte measurement of a host's vascular system are provided. In some embodiments, a continuous glucose measurement system includes a vascular access device, a sensor and sensor electronics, the system being configured for insertion into communication with a host's circulatory system.
Nº publicación: EP4631428A1 15/10/2025
Applicant:
MEDTRONIC MINIMED INC [US]
Medtronic MiniMed, Inc
Absstract of: EP4631428A1
Embodiments of the invention provide amperometric analyte sensors having optimized elements such as dexamethasone rejection membranes as well as methods for making and using such sensors. The amperometric analyte sensor apparatus comprises: a base layer; a conductive layer disposed on the base layer and comprising a working electrode; a dexamethasone rejection membrane disposed over an electroactive surface of the working electrode, wherein the interference rejection membrane comprises a poly Hema composition and an analyte sensing layer. While embodiments of the innovation can be used in a variety of contexts, typical embodiments of the invention include glucose sensors used in the management of diabetes.
BOPI
Electronic site
